Pegasys Proclick Solution For Injection 135Mcg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Pegasys ProClick: Solution for injection (135mcg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PEGINTERFERON ALFA-2a (peg in ter FEER on AL fa 2 a) is a man-made drug that acts like a protein made by the body. It is used to treat chronic hepatitis B and C infections.

In-Depth Information

Pegasys ProClick 135mcg/0.5ml Auto Injector Solution for Injection

NDC: 000040360
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Hepatitis B Infection

Sometimes used for but not FDA approved for the following conditions:
Hepatitis C Infection

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Do not leave product out of the refrigerator for more than 24 hours
Do not freeze
Discard unused portion. Do not store for later use.
Pegasys ProClick 135mcg/0.5ml Auto Injector Solution for Injection

Reported Side Effects for Pegasys ProClick 135mcg/0.5ml Auto Injector Solution for Injection

Hallucinations Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Stomach Ulcer Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Psoriasis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Blood Clot In Lung Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Lupus-like Symptoms Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Kidney Inflammation Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Intestinal Bleeding Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Inflamed Pancreas Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Psychosis Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Brain Attack Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Thoughts Of Suicide Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Moschcowitz Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Corneal Erosion Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Aplastic Anemia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Cholangitis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Inflamed Colon Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Coma Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Diabetes Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Shortness Of Breath Incidence:
<4.0%*
Severity: MODERATE
Onset: EARLY
Fatty Change Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Overactive Thyroid Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Underactive Thyroid Incidence:
<4.0%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.0-27.0%*
Severity: MODERATE
Onset: DELAYED
Eczema Vaccinatum Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
2.0-8.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
3.0-29.0%*
Severity: MODERATE
Onset: DELAYED
Low Lymphocytes Incidence:
3.0-81.0%*
Severity: MODERATE
Onset: DELAYED
Emotional Lability Incidence:
3.0-9.0%*
Severity: MILD
Onset: EARLY
Dry Skin Incidence:
4.0%*
Severity: MILD
Onset: DELAYED
Blurred Vision Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Cough Incidence:
4.0%*
Severity: MILD
Onset: DELAYED
Weight Loss Incidence:
4.0-16.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Decreased Memory Incidence:
5.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
5.0-12.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
5.0-8.0%*
Severity: MODERATE
Onset: DELAYED
Diaphoresis Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Decreased Thinking Incidence:
8.0%*
Severity: MODERATE
Onset: EARLY
Back Pain Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
>12.0%*
Severity: MILD
Onset: RAPID
Stomach Pain Incidence:
15.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
16.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
16.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
17.0%*
Severity: MILD
Onset: DELAYED
Depression Incidence:
18.0%*
Severity: MODERATE
Onset: DELAYED
Irritability Incidence:
19.0%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
19.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
19.0%*
Severity: MILD
Onset: EARLY
High Triglycerides Incidence:
20.0-36.0%*
Severity: MODERATE
Onset: DELAYED
Injection Site Reaction Incidence:
22.0%*
Severity: MILD
Onset: RAPID
Hair Loss Incidence:
23.0%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
24.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
24.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
28.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
37.0%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
37.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
54.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
56.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
56.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Pegasys ProClick

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5